(CS) AXA - Overview
Sector: Financial ServicesIndustry: Insurance - Diversified | Exchange PA (France) | Currency EUR | Market Cap: 89.990m | Total Return 3.8% in 12m
Stock
Insurance, Investments, Banking, Protection
Total Rating 34
Risk 36
Buy Signal 0.04
Market Cap:
89,990m
Avg Trading Vol: 175M EUR
Avg Trading Vol: 175M EUR
ATR:
2.26%
Peers RS (IBD): 23.3
Peers RS (IBD): 23.3
Risk 5d forecast
Volatility18.1%
Rel. Tail Risk3.66%
Reward TTM
Sharpe Ratio0.05
Alpha-3.17
Character TTM
Beta0.015
Beta Downside-0.380
Drawdowns 3y
Max DD13.69%
CAGR/Max DD1.20
Description: CS AXA
March 05, 2026
AXA SA is a French multinational insurance and asset management firm. The company operates globally, providing a diverse range of insurance products including life, savings, property, and casualty.
AXAs business model is diversified across six segments, including France, Europe, AXA XL (commercial lines), Asia, Africa & EME-LATAM, and AXA Investment Managers. This structure allows for broad geographic reach and specialized services in areas like reinsurance and asset management. The insurance sector is characterized by long-term liabilities and significant regulatory oversight.
The company also offers banking services and a variety of specialized solutions such as parametric insurance and integrated health ecosystems. Asset management services cover various asset classes and multi-manager solutions, a common practice in the investment industry to diversify risk and expertise. Investors should consider further research on ValueRay for a deeper understanding of AXAs financial performance and market position.
- Global interest rate hikes boost investment income
- Catastrophe claims increase property and casualty payouts
- Regulatory changes impact insurance product offerings
- Emerging market growth drives new policy sales
- Asset management fees fluctuate with market performance
Piotroski VR‑10 (Strict, 0-10)
6.5
| Net Income: 15.65b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.52 > 1.0 |
| NWC/Revenue: 26.18% < 20% (prev 60.26%; Δ -34.08% < -1%) |
| CFO/TA 0.05 > 3% & CFO 33.50b > Net Income 15.65b |
| Net Debt (-6.40b) to EBITDA (15.78b): -0.41 < 3 |
| Current Ratio: error (cannot be calculated; needs correct Total Current Assets and Liabilities) |
| Outstanding Shares: last quarter (2.03b) vs 12m ago -8.98% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 27.51% > 50% (prev 29.03%; Δ -1.52% > 0%) |
| Interest Coverage Ratio: 11.68 > 6 (EBITDA TTM 15.78b / Interest Expense TTM 906.0m) |
Altman Z''
0.87
| A: 0.07 (Total Current Assets 46.10b - Total Current Liabilities 0.0) / Total Assets 635.50b |
| B: 0.07 (Retained Earnings 41.41b / Total Assets 635.50b) |
| C: 0.02 (EBIT TTM 10.59b / Avg Total Assets 639.97b) |
| D: 0.07 (Book Value of Equity 41.41b / Total Liabilities 586.00b) |
| Altman-Z'' Score: 0.87 = B |
Beneish M
-1.66
| DSRI: 2.57 (Receivables 23.90b/9.90b, Revenue 176.09b/187.11b) |
| GMI: 1.01 (GM 101.1% / 102.4%) |
| AQI: 1.23 (AQ_t 0.92 / AQ_t-1 0.75) |
| SGI: 0.94 (Revenue 176.09b / 187.11b) |
| TATA: -0.03 (NI 15.65b - CFO 33.50b) / TA 635.50b) |
| Beneish M-Score: -1.66 (Cap -4..+1) = CCC |
What is the price of CS shares?
As of March 31, 2026, the stock is trading at EUR 38.81 with a total of 3,801,827 shares traded.
Over the past week, the price has changed by +2.48%, over one month by -6.39%, over three months by -5.66% and over the past year by +3.77%.
Over the past week, the price has changed by +2.48%, over one month by -6.39%, over three months by -5.66% and over the past year by +3.77%.
Is CS a buy, sell or hold?
AXA has no consensus analysts rating.
What are the forecasts/targets for the CS price?
| ISSUER | TARGET | UP/DOWN |
|---|---|---|
| Wallstreet Target Price | 46.1 | 18.7% |
| Analysts Target Price | - | - |
CS Fundamental Data Overview
March 30, 2026
Market Cap USD = 89.99b (78.00b EUR * 1.1537 EUR.USD)P/E Trailing = 11.0965
P/E Forward = 9.1075
P/S = 0.8237
P/B = 1.7326
P/EG = 1.2122
Revenue TTM = 176.09b EUR
EBIT TTM = 10.59b EUR
EBITDA TTM = 15.78b EUR
Long Term Debt = 60.49b EUR (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 15.80b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -6.40b EUR (from netDebt column, last quarter)
Enterprise Value = 71.60b EUR (78.00b + Debt 15.80b - CCE 22.20b)
Interest Coverage Ratio = 11.68 (Ebit TTM 10.59b / Interest Expense TTM 906.0m)
EV/FCF = 2.20x (Enterprise Value 71.60b / FCF TTM 32.60b)
FCF Yield = 45.53% (FCF TTM 32.60b / Enterprise Value 71.60b)
FCF Margin = 18.51% (FCF TTM 32.60b / Revenue TTM 176.09b)
Net Margin = 8.89% (Net Income TTM 15.65b / Revenue TTM 176.09b)
Gross Margin = unknown ((Revenue TTM 176.09b - Cost of Revenue TTM -1.90b) / Revenue TTM)
Tobins Q-Ratio = 0.11 (Enterprise Value 71.60b / Total Assets 635.50b)
Interest Expense / Debt = 1.89% (Interest Expense 299.0m / Debt 15.80b)
Taxrate = 23.67% (2.37b / 10.00b)
NOPAT = 8.08b (EBIT 10.59b * (1 - 23.67%))
Current Ratio = unknown (Total Current Assets 46.10b / Total Current Liabilities 0.0)
Debt / Equity = 0.33 (Debt 15.80b / totalStockholderEquity, last quarter 47.20b)
Debt / EBITDA = -0.41 (Net Debt -6.40b / EBITDA 15.78b)
Debt / FCF = -0.20 (Net Debt -6.40b / FCF TTM 32.60b)
Total Stockholder Equity = 46.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.44% (Net Income 15.65b / Total Assets 635.50b)
RoE = 33.99% (Net Income TTM 15.65b / Total Stockholder Equity 46.03b)
RoCE = 9.94% (EBIT 10.59b / Capital Employed (Equity 46.03b + L.T.Debt 60.49b))
RoIC = 7.03% (NOPAT 8.08b / Invested Capital 115.00b)
WACC = 5.27% (E(78.00b)/V(93.80b) * Re(6.04%) + D(15.80b)/V(93.80b) * Rd(1.89%) * (1-Tc(0.24)))
Discount Rate = 6.04% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -4.59%
[DCF] Terminal Value 88.44% ; FCFF base≈23.72b ; Y1≈29.26b ; Y5≈49.92b
[DCF] Fair Price = 707.7 (EV 1448.14b - Net Debt -6.40b = Equity 1454.54b / Shares 2.06b; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -5.33 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 5.03 | Revenue CAGR: 36.44% | SUE: 0.22 | # QB: 0
EPS current Year (2026-12-31): EPS=4.13 | Chg7d=-0.019 | Chg30d=-0.023 | Revisions Net=+4 | Growth EPS=+6.9% | Growth Revenue=+25.1%
EPS next Year (2027-12-31): EPS=4.45 | Chg7d=+0.008 | Chg30d=+0.009 | Revisions Net=+3 | Growth EPS=+7.7% | Growth Revenue=+4.5%
[Analyst] Revisions Ratio: +0.50 (6 Up / 2 Down within 30d for Current Year)
[Growth] Implied Growth Rate = -1.1% (Discount Rate 7.9% - Earnings Yield 9.0%)
[Growth] Growth Spread = +5.6% (Analyst 4.5% - Implied -1.1%)